A Double-Blind, Crossover, Randomized, Placebo-Controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-Phase Insulin Secretion in Type 2 Diabetic Patients

Trial Profile

A Double-Blind, Crossover, Randomized, Placebo-Controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-Phase Insulin Secretion in Type 2 Diabetic Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs Taspoglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 25 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
    • 20 Jan 2010 New source identified and integrated Roche (BP21844).
    • 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top